MAPK14 and cancer: Among the resulting hits, decreasing cell frequencies associated with Cluster 3, were nerve growth factor (NGF), the p38 MAP kinase inhibitor SB202190 and the selective histone deacetylase inhibitor MGCD0103 (Mocetinostat), the latter currently being explored in clinical trials for a variety of cancers.